Table 2 Clinical characteristics of patients with pSS-EGM and pSS-non-EGM

N

50

13

Age, years, mean (range)

52.84 ± 13.49

45.77 ± 13.31

0.105

Female, n (%)

43/50 (86.00)

12/13 (92.31)

0.888

Anti-SSA-positive (%)

39/50 (78.00)

10/13 (76.92)

1

Anti-SSB-positive (%)

25/50 (50.00)

3/13 (23.08)

0.154

ANA-positive (%)

37/50 (74.00)

5/13 (38.46)

0.036

RF-positive (%)

16/41 (39.02)

0/12 (0.00)

0.026

Duration(month)

32.39 ± 47.14

28.15 ± 64.92

0.156

CRP (8 mg/L)

8.46 ± 19.57

2.49 ± 5.42

0.542

ESR (mm/h)

37.93 ± 21.06

11.69 ± 7.30

< 0.001

IgG (g/L)

23.09 ± 8.87

14.72 ± 1.96

< 0.001

IgA (g/L)

3.84 ± 1.55

3.24 ± 0.85

0.124

IgM (g/L)

1.51 ± 0.79

1.29 ± 0.57

0.355

C3 (g/L)

1.04 ± 0.21

1.06 ± 0.18

0.751

C4 (g/L)

0.20 ± 0.08

0.24 ± 0.09

0.230

FS ≥ 1

39/50 (78.00)

11/13 (84.62)

0.888

ESSDAI

14.52 ± 10.16

1.08 ± 2.02

< 0.001

Xerophthalmia (%)

27/50 (54.00)

5/13 (38.46)

0.492

Xerostomia (%)

26/50 (52.00)

6/13 (46.15)

0.949